CD80 and glioblastoma: The clinical samples of GBM tissues were initially collected, and the biomarkers of M2 macrophage (CD206) and M1 macrophage (CD80) were examined by performing Real-Time qPCR analysis, which showed that the mRNA levels of CD206 were increased (Figure 1(a)), whereas CD80 were decreased (Figure 1(b)) in the GBM tissues compared to the adjacent normal tissues.